SLAMF6 and breast cancer: Among the NK-activating ligands that were associated with longer RFS in all BC patients (Figure 1), the prognostic values of only CD27, MICB, SLAMF6, TNFSF9, and ULBP1 were found to be independent of the BC subtype as their high expression was associated with longer RFS in all BC subtypes (Table 2).